Steroid naive eosinophilic asthma: Anti-inflammatory effects of fluticasone and montelukast

Thorax

Volumn 60, Issue 2, 2005, Pages 100-105

  Jayaram, L ^b   Pizzichini, E ^a   Lemiere C ^c   Man, S F P ^d   Cartier, A ^c   Hargreave, F E ^b   Pizzichini, M M M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b MCMASTER UNIVERSITY   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; STEROID;

ADULT; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; GEOMETRY; HEPATITIS; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MILD PERSISTENT ASTHMA; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM ANALYSIS; SPUTUM EXAMINATION; STATISTICAL SIGNIFICANCE; STEROID NAIVE EOSINOPHILIC ASTHMA; STEROID THERAPY; SYMPTOMATOLOGY;

ACETATES; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; PATIENT COMPLIANCE; PULMONARY EOSINOPHILIA; QUINOLINES; SPUTUM; TREATMENT OUTCOME;

EID: 13544251373     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.021634     Document Type: Article

References (49)

1. Boulet LP, Becker A, Berube D, et al. Canadian asthma consensus report 1999. Canadian Asthma Consensus Group. Can Med Assoc J 1999;161(11 Suppl):S1-61.
2. National Asthma Education and Prevention Program Expert Panel. Report 2: Guidelines for the diagnosis and management of asthma. Publication No 97. Bethesda, MD: National Institutes of Health, National Heart Lung, and Blood Institute, 2002:1-50.
3. Bousquet J, Chanez P, Lacoste JY. Asthma: a disease remodeling the airways. Allergy 1992;47:3-11.
4. Homer RJ, Elias JA. Consequences of long-term inflammation. Airway remodelling. Clin Chest Med 2000;21:331-43.
5. Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161:475-8.
6. Pizzichini E, Pizzichini MMM, Elthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid phase measurements. Am J Respir Crit Care Med 1996;154:308-17.
7. Jayaram L, Parameswaram K, Sears MR, et al. Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 2000;16:150-8.
8. Pizzichini MM. Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma? Eur Respir J 2002;20:1359-61.
9. 2- agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-92.
10. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95:29-33.
11. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when usod in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457-63.
12. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (oudesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
13. Dutoit JI, Salome CM, Woolcock AJ. Inhaled corticosteroicls reduce the severity of bronchial hyperresponsiveness in asthma but ora theophylline does not. Am Rev Respir Dis 1987;136:1174-8.
14. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
15. Haahtela T, Klaukka T. Societal and health care benefits of early use of inhaled steroids. Thorax 1998;53:1005-6.
16. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long-term prevention of hospitalization for asthma. Thorax 2002;57:880-4.
17. Suissa S, Ernest P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
18. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8.
19. Minogushi K, Kohno Y, Minogushi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002;121:732-8.
20. Leigh R, Vethanayagam D, Yoshida M, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002;166:1212-7.
21. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-20.
22. Reiss TF, Sorkness CA, Stricker W, et al. Effect of montelukast (MK-0476); a potent cysteinyl leukotrine receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
23. Bisgaard H, for the Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003;167:379-83.
24. Barnes NC, Miller CJ. Effect of leukotrine receptor antagonist therapy receptor antagonist therapy on the risk of asthma exacerbation in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000;55:478-83.
25. Busse W, Raphael GD, Galant S, for the Fluticasone Proprionate Clinical Research Study Group, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461-8.
26. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone proprionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000;105:1223-9.
27. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone proprionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000;105:1223-9.
28. Gibson PG, Wong BJO, Hepperle MJE, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992;22:525-32.
29. Pepys J. Skin test in diagnosis. In: Gell PGH, Coombs RRA, Lachmann PJ, eds. Clinical aspects of immunology. 3rd ed. Oxford: Blackwell Scientific Publications, 1975:55-80.
30. American Thoracic Society. Standardization of spirometry. 1994 update. Am Rev Respir Dis 1995;152:1107-36.
31. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meets ATS recommendation. Am Rev Respir Dis 1981;123:659-94.
32. Juniper EF, Cockroft DW, Hargreave FE. Histamine and methacholine inhalation test: a laboratory tidal breathing protocol. Lund, Sweden: Astra Draco AB, 1994.
33. Pizzichini MMM, Popov T, Pizzichini E, et al. Spontaneous and induced sputum compared. Am J Respir Crit Care Med 1996;154:866-9.
34. Turner MO, Johnston PR, Pizzichini E, et al. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J 1998;5:261-8.
35. Kips J, Inman MD, Jayaram L, et al. The use of induced sputum in clinical trials. Eur Respir J Suppl 2002;37:47-50s.
36. Pavord ID, Brightling CE, Wolkman G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353:2213-4.
37. van Resen ELJ, Straathof KCM, Maud AVC, et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999;54:403-8.
38. Yudkin PL, Stratton IM. How to deal with regression to the mean intervention studies. Lancet 1996;347:241-3.
39. Louis R, Sele J, Henket M, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naïve asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002;57:907-12.
40. Lee SVS, Pizzichini MMP, Marques LJ, et al. Inflamacao das vias aereas em asmaticos virgens de tratamento com esteroides: caracteristicas do escarro induzido. J Pneumol 2003;29:188-95.
41. Malmstrom K, Rodriguez-Gomez G, Guerra J, for the Montelukast/ Beclomethasone Study Group, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized control trial. Ann Intern Med 1999;16:487-95.
42. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
43. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 2001;108:503-8.
44. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asinma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9.
45. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med, 1998;158:1511-7.
46. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
47. Jayaram L, Hussack H, Boulet LP, et al. The LOMA study: effect on asthma exacerbations in the first year. Am J Respir Crit Care Med 2003;167:A976.
48. Reiss TF, Sorkness CA, Stricker W, et al. Effect of montelukast (MK-0476); a potent cysteinyl leukotrine receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
49. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotrine receptor antagonist, for the treatment of mild asthma and exercise induced bronchoconstriction. N Engl J Med 1998;339:147-52.